AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

AC Immune S.A.NASDAQ: ACIU

Other Non-Cash Items · Q4 FY2025 · quarter ended Dec 2025

Other non-cash items turns positive

Q4 FY2025 other non-cash items was CHF 938.88K, compared with -CHF 2.13M a year earlier. Trailing-twelve-month other non-cash items was CHF 606.88K.

Context

  • Other non-cash items amounted to 145.9% of revenue in FY2025, up 140.0 pp from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near CHF 938.88K or moves back toward the trailing-twelve-month quarterly average of CHF 151.72K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 938.88K+131.3% QoQ
Last fiscal yearDec 2025
CHF 5.21M+223.3% YoY
LTMDec 2025
CHF 606.88K-74.7% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+144.2%——
1 year+223.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

CHF · from the cash flow

Latest · FY2025
5.21M CHF
Year-over-year change
+223.3%

Other Non-Cash Items vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -74.7% is the 8th highest of 10, against a peer median of -46.0%.
  • Other non-cash items amounts to 17.0% of revenue for ACIU, versus a peer median of 532.5%.
ACIU Competitors
Other Non-Cash Items for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLNSilence Therapeutics plcLTM Mar 2026$70.22M USD——7620.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$67.8M USD-43.9%+0.8%218706.5%
AMRNAmarin Corporation plcLTM Mar 2026$22.77M USD-431.8%—10.6%
CLLSCellectis S.A.LTM Mar 2026$19.72M USD+30.1%—29.0%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$12.42M USD-60.9%+71.5%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$4.01M USD+59.1%+61.6%—
MREOMereo BioPharma Group plcLTM Mar 2026$2.66M USD-46.0%—532.5%
ANNXAnnexon, Inc.LTM Mar 2026$1.21M USD-85.6%——
ACIUAC Immune S.A.LTM Dec 2025CHF 606.88K CHF-74.7%—17.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$562K USD+183.4%-52.2%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$538.54K USD-63.0%——
Peer median (excluding ACIU) —-46.0%+31.2%532.5%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.